Skip to main content
Top
Published in: Clinical Rheumatology 3/2019

01-03-2019 | Original Article

Subcutaneous tocilizumab alone or with a csDMARD in rheumatoid arthritis patients: subanalysis of Italian data from a multicenter phase IIIb/IV trial

Authors: Laura Bazzichi, Francesca Nacci, Luigi Sinigaglia, Laura Bianchino, Roberto Caporali

Published in: Clinical Rheumatology | Issue 3/2019

Login to get access

Abstract

To assess, in a setting close to real life, the efficacy and safety of weekly subcutaneous tocilizumab (TCZ-SC) 162 mg, alone or with a conventional synthetic DMARD (csDMARD), in moderate-to-severe RA patients with inadequate response to DMARDs or anti-TNFα drugs. This national, multicenter, open-label, phase IIIb trial is part of an umbrella study (TOZURA). Patients were treated for 52 weeks followed by 8 weeks drug-free to evaluate immunogenicity. The primary end point was the Clinical Disease Activity Index (CDAI) change from baseline at weeks 2 and 24. Other efficacy parameters, including sleep quality, and the safety and immunogenicity were also assessed up to week 52. Of 288 patients enrolled in 43 Italian centers, 78.8% received TCZ-SC (86.8% females; mean age 54.7 ± 12.1 years; mean disease duration 7.8 ± 7.5 years; DMARD-IRs 94.7%). Of these, 78.0% completed the 52-week period and 52.0% received concomitant methotrexate. TCZ-SC yielded a significant reduction in median CDAI from baseline already at week 2, which progressed up to week 24 and remained stable thereafter (P < 0.0001 at each time point). A significant, rapid, and sustained improvement of the other efficacy variables was also observed. Patients were deemed as ready for home administration after a median of 2.0 (range 1–8) administrations, with a rate (since the last visit) of 80.6% and 95.5% at weeks 2 and 52, respectively. TCZ-SC displayed low immunogenicity and no unexpected toxicities. TCZ-SC, alone or with a csDMARD, yielded rapid and sustained efficacy in DMARD/anti-TNFα-IR RA patients, with acceptable toxicity. Home administration seems feasible.
Appendix
Available only for authorised users
Literature
1.
go back to reference Rossini M, Rossi E, Bernardi D, Viapiana O, Gatti D, Idolazzi L, Caimmi C, DeRosa M, Adami S (2014) Prevalence and incidence of rheumatoid arthritis in Italy. Rheumatol Int 34:659–664CrossRefPubMed Rossini M, Rossi E, Bernardi D, Viapiana O, Gatti D, Idolazzi L, Caimmi C, DeRosa M, Adami S (2014) Prevalence and incidence of rheumatoid arthritis in Italy. Rheumatol Int 34:659–664CrossRefPubMed
2.
go back to reference Kojima M, Kojima T, Ishiguro N, Oguchi T, Oba M, Tsuchiya H, Sugiura F, Furukawa TA, Suzuki S, Tokudome S (2009) Psychosocial factors, disease status, and quality of life in patients with rheumatoid arthritis. J Psychosom Res 67:425–431CrossRefPubMed Kojima M, Kojima T, Ishiguro N, Oguchi T, Oba M, Tsuchiya H, Sugiura F, Furukawa TA, Suzuki S, Tokudome S (2009) Psychosocial factors, disease status, and quality of life in patients with rheumatoid arthritis. J Psychosom Res 67:425–431CrossRefPubMed
3.
go back to reference Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M (2016) A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int 36:685–695CrossRefPubMedPubMedCentral Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M (2016) A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int 36:685–695CrossRefPubMedPubMedCentral
4.
go back to reference Luyster FS, Chasens ER, Wasko MCM, Dunbar-Jacob J (2011) Sleep quality and functional disability in patients with rheumatoid arthritis. J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med 7:49–55 Luyster FS, Chasens ER, Wasko MCM, Dunbar-Jacob J (2011) Sleep quality and functional disability in patients with rheumatoid arthritis. J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med 7:49–55
5.
go back to reference Løppenthin K, Esbensen BA, Jennum P, Østergaard M, Tolver A, Thomsen T, Midtgaard J (2015) Sleep quality and correlates of poor sleep in patients with rheumatoid arthritis. Clin Rheumatol 34:2029–2039CrossRefPubMed Løppenthin K, Esbensen BA, Jennum P, Østergaard M, Tolver A, Thomsen T, Midtgaard J (2015) Sleep quality and correlates of poor sleep in patients with rheumatoid arthritis. Clin Rheumatol 34:2029–2039CrossRefPubMed
6.
go back to reference Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T, CHARISMA Study Group (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817–2829CrossRefPubMed Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T, CHARISMA Study Group (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817–2829CrossRefPubMed
7.
go back to reference Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987–997CrossRefPubMed Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987–997CrossRefPubMed
8.
go back to reference Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58:2968–2980CrossRefPubMed Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58:2968–2980CrossRefPubMed
9.
go back to reference Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A et al (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67:1516–1523CrossRefPubMedPubMedCentral Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A et al (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67:1516–1523CrossRefPubMedPubMedCentral
10.
go back to reference Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomsic M, Alecock E, Woodworth T, Genovese MC (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69:88–96CrossRefPubMed Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomsic M, Alecock E, Woodworth T, Genovese MC (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69:88–96CrossRefPubMed
12.
go back to reference Desplats M, Pascart T, Jelin G, Norberciak L, Philippe P, Houvenagel E, Goeb V, Flipo RM (2017) Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study. Clin Rheumatol 36:1395–1400CrossRefPubMed Desplats M, Pascart T, Jelin G, Norberciak L, Philippe P, Houvenagel E, Goeb V, Flipo RM (2017) Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study. Clin Rheumatol 36:1395–1400CrossRefPubMed
13.
go back to reference Zhang X, Georgy A, Rowell L (2013) Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects. Int J Clin Pharmacol Ther 51:443–455CrossRefPubMed Zhang X, Georgy A, Rowell L (2013) Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects. Int J Clin Pharmacol Ther 51:443–455CrossRefPubMed
14.
go back to reference Zhang X, Chen Y-C, Fettner S, Rowell L, Gott T, Grimsey P, Unsworth A (2013) Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 51:620–630CrossRefPubMed Zhang X, Chen Y-C, Fettner S, Rowell L, Gott T, Grimsey P, Unsworth A (2013) Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 51:620–630CrossRefPubMed
15.
go back to reference Ohta S, Tsuru T, Terao K, Mogi S, Suzaki M, Shono E, Ishida Y, Tarumi E, Imai M (2014) Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). J Clin Pharmacol 54:109–119CrossRefPubMed Ohta S, Tsuru T, Terao K, Mogi S, Suzaki M, Shono E, Ishida Y, Tarumi E, Imai M (2014) Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). J Clin Pharmacol 54:109–119CrossRefPubMed
16.
go back to reference Ogata A, Tanimura K, Sugimoto T, Inoue H, Urata Y, Matsubara T, Kondo M, Ueki Y, Iwahashi M, Tohma S, Ohta S, Saeki Y, Tanaka T, the Musashi Study Investigators (2014) Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res 66:344–354CrossRef Ogata A, Tanimura K, Sugimoto T, Inoue H, Urata Y, Matsubara T, Kondo M, Ueki Y, Iwahashi M, Tohma S, Ohta S, Saeki Y, Tanaka T, the Musashi Study Investigators (2014) Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res 66:344–354CrossRef
17.
go back to reference Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, Merrill JT, Rowell L, Nasmyth-Miller C, Bao M, Wright S, Pope JE (2014) Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res 66:1653–1661CrossRef Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, Merrill JT, Rowell L, Nasmyth-Miller C, Bao M, Wright S, Pope JE (2014) Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res 66:1653–1661CrossRef
18.
go back to reference Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, Rangaraj MJ, Roane G, Ludivico C, Lu P, Rowell L, Bao M, Mysler EF (2014) A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 73:69–74CrossRefPubMed Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, Rangaraj MJ, Roane G, Ludivico C, Lu P, Rowell L, Bao M, Mysler EF (2014) A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 73:69–74CrossRefPubMed
19.
go back to reference Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bernasconi C et al (2016) FRI0215 subcutaneous tocilizumab as monotherapy or in combination with a csDMARDs in patients with rheumatoid arthritis—interim analysis of a large phase IV international umbrella study, “Tozura.”. Ann Rheum Dis 75:509–510 Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bernasconi C et al (2016) FRI0215 subcutaneous tocilizumab as monotherapy or in combination with a csDMARDs in patients with rheumatoid arthritis—interim analysis of a large phase IV international umbrella study, “Tozura.”. Ann Rheum Dis 75:509–510
20.
go back to reference Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193–213CrossRefPubMed Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193–213CrossRefPubMed
21.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRefPubMed Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRefPubMed
22.
go back to reference Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT (2010) Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588CrossRefPubMed Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT (2010) Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588CrossRefPubMed
23.
go back to reference Negoescu AF, Östör AJK (2015) Refining the management of rheumatoid arthritis: the benefits of subcutaneous tocilizumab. Rheumatol Ther 2:17–31CrossRefPubMed Negoescu AF, Östör AJK (2015) Refining the management of rheumatoid arthritis: the benefits of subcutaneous tocilizumab. Rheumatol Ther 2:17–31CrossRefPubMed
24.
go back to reference Kivitz A, Wallace T, Olech E, Borofsky M, Devenport J, Pei J, Michalska M (2016) Long-term safety and efficacy of subcutaneously administered tocilizumab for adult rheumatoid arthritis: a multicenter phase 3b long-term extension study. Rheumatol Ther 3:291–304CrossRefPubMedPubMedCentral Kivitz A, Wallace T, Olech E, Borofsky M, Devenport J, Pei J, Michalska M (2016) Long-term safety and efficacy of subcutaneously administered tocilizumab for adult rheumatoid arthritis: a multicenter phase 3b long-term extension study. Rheumatol Ther 3:291–304CrossRefPubMedPubMedCentral
25.
go back to reference Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, Rangaraj MJ, Roane G, Ludivico C, Bao M, Rowell L, Davies C, Mysler EF (2016) Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). Ann Rheum Dis 75:68–74CrossRefPubMed Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, Rangaraj MJ, Roane G, Ludivico C, Bao M, Rowell L, Davies C, Mysler EF (2016) Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). Ann Rheum Dis 75:68–74CrossRefPubMed
26.
go back to reference Burmester GR, Choy E, Kivitz A, Ogata A, Bao M, Nomura A, Lacey S, Pei J, Reiss W, Pethoe-Schramm A, Mallalieu NL, Wallace T, Michalska M, Birnboeck H, Stubenrauch K, Genovese MC (2017) Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Ann Rheum Dis 76:1078–1085CrossRefPubMed Burmester GR, Choy E, Kivitz A, Ogata A, Bao M, Nomura A, Lacey S, Pei J, Reiss W, Pethoe-Schramm A, Mallalieu NL, Wallace T, Michalska M, Birnboeck H, Stubenrauch K, Genovese MC (2017) Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Ann Rheum Dis 76:1078–1085CrossRefPubMed
27.
go back to reference Striesow F, Brandt A (2012) Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: results of a postmarketing surveillance study with a high-concentration formulation. Ther Adv Musculoskelet Dis 4:3–9CrossRefPubMedPubMedCentral Striesow F, Brandt A (2012) Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: results of a postmarketing surveillance study with a high-concentration formulation. Ther Adv Musculoskelet Dis 4:3–9CrossRefPubMedPubMedCentral
Metadata
Title
Subcutaneous tocilizumab alone or with a csDMARD in rheumatoid arthritis patients: subanalysis of Italian data from a multicenter phase IIIb/IV trial
Authors
Laura Bazzichi
Francesca Nacci
Luigi Sinigaglia
Laura Bianchino
Roberto Caporali
Publication date
01-03-2019
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 3/2019
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-018-4327-4

Other articles of this Issue 3/2019

Clinical Rheumatology 3/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.